4-chloro-m-cresol cannot detect malignant hyperthermia equivocal cells in an alternative minimally invasive diagnostic test of malignant hyperthermia susceptibility
- PMID: 15281512
- DOI: 10.1213/01.ANE.0000118110.90277.D2
4-chloro-m-cresol cannot detect malignant hyperthermia equivocal cells in an alternative minimally invasive diagnostic test of malignant hyperthermia susceptibility
Abstract
Malignant hyperthermia (MH) is an inherited skeletal muscle disorder triggered by commonly used anesthetics. Mutated ryanodine receptors have been identified as molecular targets. The sensitivity of myotubes from individuals classified by the in vitro contracture test as MH susceptible (MHS), normal (MHN), and equivocal (MHEH) was assessed for the Ca2+-releasing activity of 4-chloro-m-cresol (4-CmC) and caffeine. In this study, we sought to determine whether 4-CmC can differentiate the MH status of an individual on the basis of the release of intracellular Ca2+, particularly in regard to MHEH diagnosis. Intracellular Ca2+ concentration was determined photometrically with Fura2. Regions of the ryanodine receptor 1 harboring most of the described MH mutations were sequenced from MHS and MHEH cells. One MH mutation (Gly2434Arg) was found in one MHS individual. Results of the caffeine-induced Ca2+ release in MHS and MHN cells correlated well with the in vitro contracture test results. MHS cells showed a higher sensitivity against caffeine and, to a lesser extent, against 4-CmC. Cells of MHEH individuals showed low sensitivities against both caffeine and 4-CmC, comparable to those of the MHN group. Therefore, with myotubes, caffeine was able to discriminate between MHS and MHN cells, but both caffeine and 4-CmC failed to detect MHEH cells.
Similar articles
-
Classification of malignant hyperthermia-equivocal patients by 4-chloro-M-cresol.Anesth Analg. 1997 Jul;85(1):149-54. doi: 10.1097/00000539-199707000-00027. Anesth Analg. 1997. PMID: 9212139
-
[4-chloro-m-cresol-induced contractures of skeletal muscle specimen from patients at risk for malignant hyperthermia].Anasthesiol Intensivmed Notfallmed Schmerzther. 1997 Sep;32(9):541-8. doi: 10.1055/s-2007-995108. Anasthesiol Intensivmed Notfallmed Schmerzther. 1997. PMID: 9417254 German.
-
3,5-Di-t-butyl catechol is a potent human ryanodine receptor 1 activator, not suitable for the diagnosis of malignant hyperthermia susceptibility.Pharmacol Res. 2012 Jul;66(1):80-7. doi: 10.1016/j.phrs.2012.03.012. Epub 2012 Mar 28. Pharmacol Res. 2012. PMID: 22480578
-
Ryanodine receptor mutations in malignant hyperthermia and central core disease.Hum Mutat. 2000;15(5):410-7. doi: 10.1002/(SICI)1098-1004(200005)15:5<410::AID-HUMU2>3.0.CO;2-D. Hum Mutat. 2000. PMID: 10790202 Review.
-
Malignant hyperthermia: a pharmacogenetic disease of Ca++ regulating proteins.Curr Mol Med. 2002 Jun;2(4):347-69. doi: 10.2174/1566524023362429. Curr Mol Med. 2002. PMID: 12108947 Review.
Cited by
-
Effects of Remimazolam on Intracellular Calcium Dynamics in Myotubes Derived from Patients with Malignant Hyperthermia and Functional Analysis of Type 1 Ryanodine Receptor Gene Variants.Genes (Basel). 2023 Oct 27;14(11):2009. doi: 10.3390/genes14112009. Genes (Basel). 2023. PMID: 38002952 Free PMC article.
-
Functional analysis of ryanodine receptor type 1 p.R2508C mutation in exon 47.J Anesth. 2009;23(3):341-6. doi: 10.1007/s00540-009-0746-3. Epub 2009 Aug 14. J Anesth. 2009. PMID: 19685112
-
Preclinical model systems of ryanodine receptor 1-related myopathies and malignant hyperthermia: a comprehensive scoping review of works published 1990-2019.Orphanet J Rare Dis. 2020 May 7;15(1):113. doi: 10.1186/s13023-020-01384-x. Orphanet J Rare Dis. 2020. PMID: 32381029 Free PMC article.
References
-
- Wappler F, Anetseder MJ, Baur CP, et al. Multicentre evaluation of in-vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility. Eur J Anaesthesiol 2003;20:528–36.
-
- Ording H. In vitro contracture test for the diagnosis of malignant hyperthermia following the protocol of the European MH group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. Acta Anaesthesiol Scand 1997;41:955–66.
-
- Pessah I, Stambuk R, Casida J. Ca2+-activated ryanodine binding: mechanisms of sensitivity and intensity modulation by Mg2+, caffeine, and adenine nucleotides. Mol Pharmacol 1987;31:232–8.
-
- Sei Y, Brandom BW, Bina S, et al. Patients with malignant hyperthermia demonstrate an altered calcium control mechanism in B lymphocytes. Anesthesiology 2002;97:1052–8.
-
- Klingler W, Baur C, Georgieff M, et al. Detection of proton release from cultured human myotubes to identify malignant hyperthermia susceptibility. Anesthesiology 2002;97:1059–66.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous